TLSA · Tiziana Life Sciences Ltd

Tiziana Life Sciences announced the publication of positive preclinical data on bioRxiv demonstrating that its lead candidate, intranasal foralumab, attenuates neuroinflammation and improves cognitive function in a mouse model of Long COVID. The study, conducted by researchers from Yale University and Brigham and Women's Hospital, showed that nasal anti-CD3 treatment reduced neuroinflammation, boosted regulatory T cells in the brain, restored hippocampal neurogenesis, and improved short-term memory. The data also included human observational findings showing lower circulating Treg levels in Long COVID patients with neurological symptoms, supporting the translational relevance of the approach. Dr. Howard L. Weiner, a co-corresponding author and Chair of Tiziana's Scientific Advisory Board, highlighted the broad therapeutic window and the lack of impact on antiviral immunity as key advantages. CEO Ivor Elrifi noted that these results validate the therapeutic potential of the intranasal foralumab platform, which is currently being studied in an Expanded Access Program and a Phase 2a trial for non-active secondary progressive multiple sclerosis, with additional programs in MSA, Alzheimer's disease, and ALS.